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Clinical Features and Sleep Analysis 
of Chinese Patients with Fatal 
Familial Insomnia
Liyong Wu1, Hui Lu1, Xianling Wang1, Jia Liu1, Chaoyang Huang1, Jing Ye1, Cuijiang Li1, Jun 
Lu2, Yuping Wang1, Jianping Jia1 & Shuqin Zhan1
This study aimed to examine clinical features, sleep, abnormal sleep-wake transition and non-sleep 
disturbances as well as lab tests in Chinese fatal familial insomnia (FFI) subjects. Patients with confirmed 
clinical and laboratory diagnosis of FFI have been retrospectively reviewed. The clinical features and 
the results of the complementary tests, including polysomnography (PSG), brain imaging and genetic 
analysis, were used. Two male and three female patients were recruited in this study. Three of the five 
patients had more comprehensive family medical records. The most typical clinical manifestations in 
all 5 patients were sleep disturbances, including insomnia, laryngeal stridor, sleep breath disturbance, 
and sleep-related involuntary movements. PSG of all these five cases showed reduction in total sleep 
time, sleep fragmentation, abnormal short non-rapid eye movement - rapid eye movement (REM) 
cycling, REM sleep reduction or loss, and REM sleep instruction in wakefulness. Patient 2's emission 
tomography scan demonstrated a reduction in glucose uptake in the left thalamus and bilateral inferior 
parietal lobe. In summary, Chinese FFI patients are typically characterized by organic sleep related 
symptoms, rapidly progressive dementia and sympathetic symptoms. We propose that structural 
damages in the thalamus and cortex are mostly responsible for clinical manifestations of FFI.
Fatal familial insomnia (FFI) is a rare prion disease first described by Lugaresi et al., in 19861. The prevalence 
of FFI is one case per a million population per year, with only about 57 cases in 27 kindreds have been reported 
worldwide2.
FFI is an autosomal dominant disease that harbors a missense GAC to AAC mutation at codon 178 of the 
PRNP prion protein gene located on chromosome 20, along with the presence of the methionine polymorphism 
at position 129 of the mutant allele3, 4. Pathologically, FFI is characterized by predominant thalamic degeneration 
especially in the medio-dorsal and anterio-ventral nuclei5, 6. Phenotypic variability is a perplexing feature of FFI. 
FFI is mainly characterized by prominent sleep impairment combined with neuropsychiatric disorders, dysau-
tonomia and motor dysfunction7. Polysomnography (PSG) recordings document the biophysiological changes 
that occur during sleep. In FFI, PSG has disclosed a severely reduced total sleep time, reduced rapid eye move-
ment (REM) sleep and abnormal stage shifts. In some cases, FFI was characterized by the lack of REM-associated 
muscle atonia and the presence of jerky activity of limb muscles and irregular breathing8.
Irregular breathing, hypnic jerks, propriospinal myoclonus at the wake-sleep transition, and quasi-purposeful 
limb gestures are considered to be characteristic features of FFI6, 7. Further, husky voice was reported in 22% of 
FFI patients in Germany9. Nevertheless, the mechanism and diagnostic value of sleep related respiratory distur-
bance and movement disorder in FFI have not been studied thoroughly yet. Here, we have analyzed the clinical 
manifestations and biological changes, especially the sleep related symptoms, PSG and brain imaging results of 
five Chinese patients diagnosed with FFI. This study aims to understand the pathogenesis of sleep related disor-
ders in FFI.
Results
Clinical characteristics and neurological features. A total of five FFI patients of Chinese Han decent (2 
males and 3 females) were enrolled in the current study. The median age at FFI onset was 46.4 years (from 19 to 62 
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years) and the duration of the course of FFI ranged from 8 to 18 months. The most prominent clinical manifesta-
tions in all five patients was sleep disturbances that included insomnia, laryngeal stridor, sleep breath disturbance, 
oneiric or stuporous episodes with hallucinations and confusion, and sleep-related involuntary movements (such 
as hypnic jerks, restless sleep with frequent changes in body position and twitchy non-purposeful movement of 
limbs). Furthermore, we have observed the development of a rapidly progressive dementia (RPD) along with psy-
chiatric symptoms in all patients. MMSE (mini-mental state examination) scores of case 1 and case 2 were only 
4 (Normal reference ≥ 20), CDR (clinical dementia rating) of case 5 was 2. Other patients had severe dementia 
and they could not complete cognitive scales. Progressive sympathetic symptoms i.e. hypertension, sweating, 
tachycardia, and irregular breathing were also presented by the patients enrolled in this study. Ataxia, pyramidal 
sign, extrapyramidal sign and dysarthria were also observed. The main clinical features and neurological features 
of these five cases are summarized in Table 1.
Familial medical history and genetic analysis. Patients 1 and 2 were siblings, and interviews with fam-
ily members have noted that their mother and an elder brother had similar FFI symptoms. Furthermore, the 
mother of Patient 5 died at the age of 70 years old due to rapid progressive dementia (RPD). The other two 
patients (Patients 3 and 4) had no known family history.
Gene sequencing of DNA extracted from the peripheral blood leukocytes revealed that all five patients had a 
D178N mutation with methionine/methionine homozygosity at the polymorphic 129 codon of the PRNP gene. 
Seven family members of Patients 1 and 2 were screened for PRNP gene mutation. Other family members were 
not screened due to lack of consent or prior death. Results of the screened family members demonstrated that the 
healthy control subjects number II-6, III-6, III-11, III-13, and III-14 were free of the PRNP D178N mutation and 
subjects number III-10 and III-15 were clinically healthy carriers of the PRNP D178N mutation (Fig. 1). Patient 
3’s mother was also screened for PRNP gene mutation, and she was also a carrier of the D178N mutation without 
displaying the clinical FFI symptoms (data not shown).
The expression of 14-3-3 protein, EEG analysis, and brain imaging. ELISA results confirmed that 
all patients were negative for the CSF 14-3-3 protein, consistent with previous reports indicating that 14-3-3 
protein is usually normal or nonspecifically changed in FFI10. EEG showed diffuse slow waves without periodic 
spike discharges in the five patients, and the brain MRI did not reveal any abnormalities (data not shown). SPECT 
performed on Patient 1 indicated a decline in blood perfusion of the bilateral thalamus, basal ganglia, and the 
medial temporal lobe (Fig. 2). Furthermore, MRS analysis for Patient 1 showed a declined level of N-aceytl aspar-
tate (NAA) in the left thalamus (data not shown). Patient 2 underwent a PET scan, which demonstrated decreased 
glucose uptake in the left thalamus and bilateral inferior parietal lobe (Fig. 3).
Case 
1
Case 
2
Case 
3
Case 
4
Case 
5
Gender M F F F M
Age at onset (years) 62 60 19 36 55
Onset to diagnosis duration (months) 3 5 3 8 11
Onset to death duration (months) 12 11 8 10 18
Cluster A—sleep-related symptoms
Insomnia + + + + +
Sleep-related involuntary movements + + + + +
Sleep-related dyspnea + + + + +
Laryngeal stridor + + + + +
Cluster B—neuropsychiatric symptoms
RPD + + + + +
Psychiatric symptoms + + − + +
Ataxia − + + + +
Pyramidal sign − − + + −
Parkinsonism − − − − +
Cluster C–progressive sympathetic symptoms
Autonomic symptoms
Hypertension + + − + −
Sweating + + − + +
Tachycardia + − + + −
Irregular breathing − − + − −
Table 1. Clinical characteristics of the five FFI patients. RPD: rapidly progressive dementia. +: symptom/sign 
observed, −: symptom/sign not observed. Psychiatric syndromes included hallucination, personality change, 
depression, anxiety, aggressiveness, disinhibition, listlessness etc. Autonomic signs include hypertension, 
sweating, tachycardia, irregular breathing etc. Sleep-related involuntary movements included frequent changes 
in the body position and twitchy non-purposeful movements of limbs during sleep.
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PSG analysis shows signs of sleep-related respiratory disturbance and leg-movement. All 
five patients enrolled in this study underwent PSG. The results demonstrated an early reduction in the 
sleep spindles and K complexes, a drastic reduction in the total sleep time by about 50% (average total sleep 
amounts = 212.3 ± 26.6 minutes), and decreased sleep efficiency. In addition, disruptions of the normal cyclic 
sleep organization, especially the loss or decreased ratio of REM phase and prolonged sleep latency of REM were 
also detected. In Patient 3, REM sleep occurred directly from wakefulness. The PSG indices for sleep efficiency 
and sleep organization are listed in Table 2. Moreover, PSG identified sleep apnea syndrome in all FFI patients, 
characterized by obstructive apnea/hypopnea and laryngeal stridor in the NREM stage. We observed involuntary 
movements in these five patients during sleep, mostly during the NREM stage 2. We did not detect PLMS. The 
PSG indices for sleep-related respiratory disturbance and leg-movement are listed in Table 3.
Hypnogram analysis. Finally, the hypnogram analysis for the five FFI patients has revealed a decreased 
sleep efficiency and disruption of the normal cyclic sleep organization. In contrast, the healthy control partici-
pants successfully completed several sleep cycles (Fig. 4).
Figure 1. The pedigree of case 1(II-7) and case 2(II-9). II-7 is the proband of this pedigree (arrow). II-7 and 
II-9 are respectively Patient 1 and Patient 2 who carried PRNP D178N mutation. Additionally, seven family 
members were screened for PRNP gene mutation: II-6, III-6, III-11, III-13, and III-14 were healthy participant 
free of PRNP D178N mutation; III-10 and III-15 were clinically healthy carriers of the PRNP D178N mutation. 
Other family members were not screened due to lack of consent or prior death.
Figure 2. SPECT analysis of FFI patients. Patient 1 SPECT image showing reduced blood flow perfusion in 
bilateral temporal lobes, bilateral basal ganglia, and bilateral thalamus.
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Discussion
FFI is a rare fatal genetic disease that affects both genders equally. The mean age at disease onset is approximately 
50 years (range, 21–62 years), and the FFI duration varied from 7 to 72 months7, 11. Increased insomnia and 
sleep-wake cycle disruption are the clinical hallmarks of FFI. In this study, we reported the clinical aspects as well 
as the analysis of sleep cycle and sleep-related disturbances for five Chinese Han patients. We have compared 
symptoms of Chinese FFI patients with FFI patients reported from other countries, especially those from Italy 
Figure 3. PET analysis of FFI patients. PET image for Patient 2 indicating reduced glucose metabolism in the 
bilateral frontal and parietal lobes and left thalamus.
Case 1 Case 2 Case 3 Case 4 Case 5 Ref.
Time in bed (min) 509.0 513.0 593.5 549.5 614.0 419–464
Total sleep time (min) 167.0 269.5 145.5 277.5 202.0 402–449
Sleep efficiency (%) 32.8 52.5 24.5 50.5 32.9 85–98
NREM Stage 1 (%) 0.6 5.2 3.8 4.1 5.0 2–5
NREM Stage 2 (%) 32.9 24.1 68.0 31.4 59.2 45–55
NREM Stage 3 (%) 66.5 70.7 16.2 61.3 25.5 20–25
REM (%) 0 0 12.0 3.2 10.4 20–25
Latency to REM stage (min) — — 339.0 208.5 117.5 90–110
Table 2. Sleep efficiency and sleep organization indices for the five FFI patients. Ref. stands for reference value 
range; REM: rapid eye movement; NREM: Non- rapid eye movement.
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and Germany, and no major differences were found. Patient 3 had an early onset of FFI at the age of 19 years. To 
the best of our knowledge, this is the youngest FFI patient ever reported. Genetic analysis of the PRNP gene con-
firmed that Patient 3’s mother was a healthy carrier of the D178N mutation, suggesting that PRNP gene mutation 
may have an autosomal dominant trait with incomplete penetrance.
The alterations in the sleep cycle in the five FFI cases were investigated by PSG recording. All patients showed 
a declined sleep efficiency and disruption of the cyclic sleep organization. The recording revealed abortion of the 
REM sleep or reduction of REM and increased latency to reach the REM stage. Furthermore, PSG results revealed 
an early reduction in the sleep spindles and K complexes in our patients, and these results came in accordance 
with previous studies1–3. Sleep spindles and K-complexes indicate the transition from light to deep NREM sleep. 
It has been confirmed that sleep spindles are produced by the thalamus12. Therefore, the loss of the sleep spindles 
and K-complexes suggests a decline in thalamic function8.
In this study, we discovered characteristic sleep features that were rarely reported in previous FFI cases, i.e., 
sleep apnea syndrome, laryngeal stridor, and sleep-related involuntary movements. In good agreement with these 
clinical symptoms, PSG recorded obstructive apnea/hypopnea, laryngeal stridor, and NREM stage 2 involuntary 
movement in the five patients enrolled in this study. Therefore, it is plausible to speculate that active laryngeal nar-
rowing during inspiration led to the development of obstructive apnea/hypopnea and laryngeal stridor in patients 
with FFI. The paralysis of the posterior cricoarytenoid muscle was reported to cause passive laryngeal narrowing 
producing the inspiratory stridor13. In the five cases enrolled in this study, we did not observe PLMS events; 
Case 1 Case 2 Case 3 Case 4 Case 5 Ref.
BMI 23 20.8 19.2 19.5 20.5 18–24
Baseline oxygen saturation 95 97 97 97 94
Minimum oxygen saturation 83 89 86 91 76
AHI 10.8 7.8 41.6 4.3 18.7 <5
Obstructive apnea + + + + + −
Laryngeal stridor + + + + + −
NREM limb movements 425 951 225 557 229 −
REM limb movements 0 0 0 2 4 −
PLMS index 0 0 0 0 0 <5
Table 3. Sleep-related respiratory disturbance and leg-movement indices of the five FFI patients. AHI: apnea/
hypopnea index; PLMS: periodic leg movement in sleep; +: symptom/sign observed; −: symptom/sign not 
observed.
Figure 4. Hypnogram of a healthy control and the five FFI patients. The 5 FFI patients presented with 
decreased sleep efficiency and disruption of the normal cyclic sleep organization (horizontal axis in sleep 
hours). W: wake, R: REM, N1-3: NREM sleep stages.
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however, we noticed involuntary limb movements, especially in NREM stage 2. This result came in accordance 
with previous studies that reported hypnic jerks, quasi-purposeful limb gestures, and propriospinal myoclonus 
atypical to the NREM stage2, 6, 7. It was proposed that the abnormal involuntary movements during sleep were 
attributed to the thalamus14, 15.
The histopathological hallmark of FFI is severe neuronal loss and deposition of the pathogenic prion 
protein (PrPSc)16. Previous postmortem neuropathological studies revealed severe atrophy of the thalamus, 
particularly in the anteroventral and dorsomedial thalamic nuclei, and the inferior olives5, 6. Additionally, 
moderate atrohpy of the cortex and basal ganglia were previously observed in FFI cases17. In this study, rou-
tine imaging of the brain did not reveal characteristic FFI features except for variable degrees of cerebral and 
cerebellar atrophy. Flourodeoxyglucose (18F) PET scan uncovered a profound bilateral thalamus with less pro-
nounced cingular hypometabolism compared with the FFI signature image18, 19. In accordance with previously 
published data, the SPECT scan of Patient 1 and PET scan of Patient 2 in our study confirmed hypometabolism 
in the thalamus. Bar et al. previously reported that hypometabolism was confined to the thalamus in the earlier 
stages of the disease18.
Previous histopathological studies indicated severe neuronal loss in the thalamus17. Therefore, it was hypoth-
esized that the dysregulation of the sleep-wake cycle is attributed to thalamic lesions20. However, animal studies 
showed that the thalamus is not critical or necessary for sleep-wake regulation21. Although thalamic strokes may 
cause hypersomnance, further analysis suggested that those strokes often extend to the hypothalamus and mid-
brain, which interferes with the ascending arousal projections. We speculate that basal ganglia-cortex circuits may 
also be involved in the regulation of the sleep-wake cycle. In this study, SPECT and PET scans revealed that basal 
ganglia and the cerebral cortex were affected in FFI. Furthermore, results obtained from rat models with induced 
lesions revealed that the basal ganglia are necessary for sleep architecture22, 23.
In conclusion, in this study, we analyzed the clinical features and sleep patterns of five FFI cases. We observed 
decreased sleep efficiency and disruption of the normal cyclic sleep organization. Nevertheless, this study had 
a few limitations like the small number of examined cases and the absence of histopathological data. In future 
studies, we will include a larger number of FFI cases, perform a detailed histopathological study, and use MRS, 
SPECT, and PET scans to elucidate the mechanism of FFI.
Materials and Methods
Ethics Statement. This study protocols outlined in this manuscript were approved by the Ethics Committee 
and local Institutional Review Board (IRB) of Xuan Wu Hospital, Capital Medical University, Beijing. All meth-
ods and experiments were performed in accordance with the relevant guidelines and regulations. All patients and 
healthy participants enrolled in the study signed an informed written consent specifically approved for this study 
prior to the study commence.
Subjects. This was a retrospective study that included five Chinese patients of Han descent who had been 
diagnosed with FFI and admitted to Xuan Wu Hospital (Beijing) from 2009 to 2014. The patients were diagnosed 
according to the FFI diagnosis criteria mentioned previously9. The clinical and phenotypic features of FFI were 
recorded for each patient at the time of admission.
Genetic and biochemical analysis for 14-3-3 protein epxression and PRNP gene muta-
tion. Blood samples were obtained from all patients as well as several healthy control family members of the 
sibling patients #1 and #2 and patient’s #3 mother. PRNP gene mutation was detected in DNA isolated from the 
peripheral blood leukocytes as previously detailed16, 24. The 14-3-3 protein analysis was performed on cerebrospi-
nal fluid samples by enzyme-linked immunosorbent assay (ELISA; Beijing TIANGEN) following the manufac-
turer’s protocol as described previously25.
EEG and brain imaging. EEG and brain magnetic resonance imaging (MRI) were performed for all five 
patients. In addition, Patient 1 underwent brain single photon emission computed tomography (SPECT) to detect 
blood flow perfusion and magnetic resonance spectrum (MRS). Patient 2 underwent a FDG positron emission 
tomography (PET) scan to illustrate the glucose metabolism of brain.
PSG analysis. Each patient underwent standard PSG (E-Series, Compumedics Limited, Abbotsford, 
Australia) study. The sleep-related laryngeal stridor, sleep breath disturbance, and involuntary movements were 
recorded. Sleep scoring was carried out for 30-second epochs according to AASM scoring criteria 2012. Next, 
sleep structure, sleep efficiency (total sleep time/total time in bed ×100%), arousal, periodic limb movement in 
sleep (PLMS) indices (AI and PLMS-I) (number of arousals and PLMS per hour of sleep), and the calculated AHI 
(apnea + hypopnea index) were evaluated.
Hypnogram analysis. Sleep stages (wake, N1, N2, N3, and REM sleep) were scored offline according to the 
American Academy of Sleep Medicine (AASM) scoring criteria by visual and spectral inspection of 30-second 
EEG epochs26.
Statistical analysis. In this study, the SPSS software was used to evaluate statistical significance. Differences 
in measured variables were assessed by using Student’s t test or Wilcoxon rank-sum test with nonparametric data. 
Results were considered statistically significant at P < 0.05.
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